


PRODUCT INFORMATION



PFK15

Item No. 17689

CAS Registry No.: 4382-63-2
Formal Name: 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one
MF: C₁₇H₁₂N₂O
FW: 260.3
Purity: ≥95%
UV/Vis.: λ_{max}: 232, 278, 330 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PFK15 is supplied as a crystalline solid. A stock solution may be made by dissolving the PFK15 in the solvent of choice, which should be purged with an inert gas. PFK15 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of PFK15 in these solvents is approximately 1, 10, and 20 mg/ml, respectively.

PFK15 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, PFK15 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. PFK15 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) is a bifunctional enzyme that contains distinct domains for the phosphorylation of fructose 6-phosphate and the dephosphorylation of fructose 2,6-bisphosphate. PFKFB3 protein expression is elevated in most tumor types.^{1,2} PFK15 is a selective inhibitor of PFKFB3 (IC₅₀ = 207 nM).³ It has no significant inhibitory effect on any member of a panel of 96 other kinases, and does not inhibit purified 6-phosphofructo-1-kinase, hexokinase, phosphoglucose isomerase, or PFKFB4. PFK15 rapidly induces apoptosis in transformed cells, suppresses glucose uptake and growth of Lewis lung carcinomas in syngeneic mice, and yields antitumor effects in human xenograft models of cancer in athymic mice.³

References

1. Atsumi, T., Chesney, J., Metz, C., *et al.* High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. *Cancer Res.* **62(20)**, 5881-5887 (2002).
2. Seo, M., Kim, J.-D., Neau, D., *et al.* Structure-based development of small molecule PFKFB3 inhibitors: A framework for potential cancer therapeutic agents targeting the Warburg effect. *PLoS One* **6(9)**, e24179 (2011).
3. Clem, B.F., O'Neal, J., Tapolsky, G., *et al.* Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. *Mol. Cancer Ther.* **12(8)**, 1461-1470 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/04/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM